New data on pharmacological properties and indications of magnesium

New Perspectives in Magnesium Research: Nutrition and Health

Volumn , Issue , 2007, Pages 127-139

  Serrano, Pedro ^a   Soria, Maríasol ^a   Escanero, Jesús F ^a  

^a UNIVERSITY OF ZARAGOZA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 54049105895     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-84628-483-0_11     Document Type: Chapter

References (65)

1. Hadj A, Pepe S, Marasco S, Rosenfeldt F. The principles of metabolic therapy for heart disease. Heart Lung Circ 2003;12:S55-S62
2. Durlach J. Magnesium in Clinical Practice. London: John Libbey; 1998
3. 2+ and vascular contractility. Miner Electrolyte Metab 1993;19:323-336
4. Erne P, Bolli P, Burgissen E, Buhler F. Correlation of platelet calcium with blood pressure: Effect of antihypertensive therapy. N Engl J Med 1984;319:1084-1088
5. Resnick LM. Intracellular free magnesium in erythrocytes of essential hypertension: Relation to blood pressure and serum divalent cations. Proc Natl Acad Sci U S A 1984;81:6511-6515
6. Resnick LM. Lonic basis of hypertension, insulin resistance, vascular disease, and re lated disorders. Am J Hypertens 1993;6:123S-134S
7. Rodríguez LM. Estudio de Magnesio Intra celular en la Hipertensión Arterial Esencial Antes y Después del Tratamiento [dissertation]. Zaragoza, Spain: Facultad de Medicina de Zaragoza; 1991
8. Lawrence M, Resnick MD. Cellular calcium and magnesium metabolism in the pathophysiology and treatment of hyperten sion and related metabolic disorders. Am J Med 1992;93(suppl 12A):2A11S-2A20S
9. James MFM. Clinical use of magnesium infusions in anesthesia. Anesth Analg 1992;74:129-136
10. Iseri LT, French JH. Magnesium: Natures physiologic calcium blocker. Am Heart J 1984;108:188-193
11. 2+ channels in smooth muscle and endotelial cells of human allantochorial placental vessels. Magnes Res 2001;14: 11-18
12. Farese RV. The phosphatidate-phosphoinositide cycle: An intracellular messenger system in the action of hormones and neurotransmitters. Metabolism 1983;32: 628-641
13. Vink R, Cernak I. Regulation of intracellular free magnesium in central nervous system injury. Frontiers Biosci 2000;5:656-665
14. Hayes RL, Jenkins LW, Lyeth BG. Neurotransmitter mediated mechanisms of traumatic brain injury: Acetylcholine and excitatory amino acids. In: Jane JA, Anderson DK, Tomer JC, Young W, eds. Central Nervous System Trauma Status Report -1991. New York: Mary Ann Liebert; 1992:173-188
15. Faden AI, Demediuk P, Panter SS, Vink R. Excitatory aminoacids, N-methyl-D-Aspartatereceptors and traumatic brain injury. Science 1989;244:798-800
16. Nowak L, Bregstovski P, Ascher P, Herbert A, Prochiantz A. Magnesium gates glutamate-Activated channels in mouse central neurons. Nature 1984;307:462-465
17. Choi DW. Excitotoxic cell death. J Neurobiol 1992;23:1261-1276
18. 2+ blockade of NMDA current in mechanically injured neurons. Science 1996; 274:1921-1923
19. Weis MT, Saunders C. Magnesium and arachidonic acid metabolism. Magnes Res 1993;6:179-190
20. Reddy TS, Bazan NG. Kinetic properties of araquidonil-coenzyme A syntetase in rat brain micrososmes. Arch Biochem Biophys 1983;226:125-133
21. Vink R. Phospholipase C activiti reduces free magnesium concentration. Biochem Biophys Res Commun 1989;165:913-918
22. Hannum YA. The sphimgomyelin cycle: A prototypic sphingolipid signaling pathway. Adv Lipid Res 1993;25:27-40
23. Liu B, Hannun YA. Inhibition of the neutral magnesium-dependent sphingomyelinase by glutathione. J Biol Chem 1997;272:16281-16287
24. Gunther T, Hollriegl V, Vommann J, Bubeck J, Classen HG. Increased lipid peroxidation in rat tissues by magnesium deficiency and vitamin E depletion. Magnes Bull 1994;16:38-43
25. Hall ED. The role of oxygen radicals in traumatic injury. Clinical implications. J Emerg Med 1993;11:31-36
26. Awasthy D, Church DF, Torbati D, Carey ME, Prior W. Oxidative stress following traumatic brain injury in rats. Surg Neurol 1997;47:575-581
27. Durlach J, Guiet-Bara A, Pages N, Bac P, Bara M. Magnesium chloride or magnesium sulfate: A genuine question. Magnes Res 2005;18:187-192
28. Teo KK, Yusuf S, Collins R, et al. Effects of intravenous magnesium in suspected acut myocardial infarction: Overview of randomised trials. BMJ 1991;303:1499-1503
29. Woods KL, Fletcher S, Roffe C, Haider Y. Intravenous magnesium sulphate in suspected acut myocardial infarction: Results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339:1553-1558
30. Woods KL, Fletcher S. Long-Term outcome after intravenous magnesium sulphate in suspected acut myocardial infarction: The second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994;343:816-819
31. Fourth International Study of Infarct Survival Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intra venous magnesium sulphate in 58,050 patients with suspected acut myocardial infartion. Lancet 1995;345:669-685
32. The Magnesium in Coronaries (MAGIC) Trial Investigators. Early administration of intravenous magnesium to high-risk patients with acut myocardial infarction in the Magnesium in Coronaries (MAGIC) trial: A randomised controlled trial. Lancet 2002;360:1189-1196
33. Galloe AM, Rasmussen HS, Jorgensen LN. Influence of oral magnesium supplementation on cardiac events among survivors of an acut myocardial infarction. BMJ 1993;307:585-587
34. Van de Werf F, Ardissino D, Betru A, et al. Management of acut myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2003;24:28-66
35. Antman EM, Anbe DT, Armstrong PW, et al. American College of Cardiology; American Heart Association; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction -executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acut myocardial infarction) [published correction appears in J Am Coll Cardiol 2005;45:1376]. J Am Coll Cardiol 2004;44:671-719
36. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J 2001;22:1374-1450
37. Nieminen MS, Böhm M, Cowie MR, et al. Executive summery of the guidelines on the diagnosis and treatment of acut heart failture: The Task Force on Acut Heart Failture of the European Society of Cardiology. Eur Heart J 2005;26:384-416
38. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82. Euratum in J Am Coll Cardiol 2006;47:1503-1505
39. Chobanian AV, Bakris Gl, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003;289:2560-2571
40. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21:1983-1992
41. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefi t from magnesium sulphate? The Magpie Trial: A randomised placebo-controlled trial. Lancet 2002;359:1877-1890
42. Lucas MJ, Leveno KJ, Cunningham, FG. A comparison of magnesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med 1995;333:201-205
43. Belfort MA, Anthony J, Saade GR, Allen JC Jr, et al. A comparison of magnesium sulfate with nimodipine for the prevention of eclampsia. N Engl J Med 2004;348:304-311
44. World Health Organization (WHO). Managing Complications in Pregnancy and Childbirth: A Guide for Midwives and Doctors: Headache, Blurred Vision, Convul sions or Loss of Consciousness, Elevated Blood Pressure. Available from: Http://www.who.int/reproductive-health/impact/Symptoms/Headache-blood- pressure-S35-S56.html (accessed June 2006
45. The Eclampsia Trial Collaborative Group. Which anticolvulsant for women with eclampsia: Evidence from the Collaborative Eclampsia Trial [published correction in Lancet 1995;346:358]. Lancet 1995;345:1455-1463
46. Duley L, Henderson-Smart D. Magnesium Sulphate Versus Phenytoin for Eclampsia. Chichester: Wiley; 2004
47. Duley L, Henderson-Smart D. Magnesium Sulphate Versus Diazepam for Eclampsia. Chichester: Wiley; 2004
48. Duley L, Henderson-Smart D. Magnesium Sulphate Versus Lytic Cocktail for Eclampsia. Chichester: Wiley; 2004
49. Wilkins IA, Lynch L, Mehalek KE, Berkowitz GS, Berkowitz RL. Efficacy and side effects of magnesium sulfate and ritodrine as tocolytic agents. Am J Obstet Gynecol 1988;159:685-689
50. Chau AC, Gabert HA, Miller JM Jr. A prospective comparison of terbutaline and magnesium for tocolysis. Obstet Gynecol 1992;80:847-851
51. Crowther CA, et al. Magnesium Sulphate for Preventing Preterm Birth in Threatened Preterm Labour. Chichester: Wiley; 2004
52. Schendel DE, Beng CJ, Yeargm-Allsopp M, Boyle CA, Decoufl e P. Prenatal magnesium sulfate exposure and the risk of cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. JAMA 1996;276:1805-1810
53. Mittendorf R, Dambrosia J, Dammann O. Association between maternal serum ionised magnesium levels at delivery and neonatal intraventricular hemorrhage. J Pediatr 2002;140:540-546
54. Mittendorf R, Pryde P, Phoshnood B, Lee KS. If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact? Obstet Gynecol 1998;92:308-311
55. Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI). Global Strategy for Asthma Management and Prevention. Bethesda, MD: Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI); 2005
56. Scarfone RJ, Loiselle JM, Joffe MD, et al. A randomized trial of magnesium in the emergency department treatment of children with asthma. Ann Emerg Med 2000;36:572-578
57. Silverman RA, Osborn H, Runge J, et al. Acut Asthma/Magnesium Study Group. IV magnesium sulfate in the treatment of acut severe asthma: A multicenter randomized controlled trial. Chest 2002;122:489-497
58. Hughes R, Goldkorn A, Masoli M, et al. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: Randomised placebo-controlled trial. Lancet 2003;21;361:2114-2117
59. National Asthma Education and Prevention Program. Managing Asthma during Pregnancy: Recommendations for Pharmacologic Treatment. Bethesda, MD: National Heart, Lung, and Blood Institute; 2005
60. Skorodin MS, Tenholder MF, Yetter B. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 1995;155:496-500
61. Chandran S, Haqueb ME, Wickramasinghe HT, et al. Use of magnesium sulphate in severe persistent pulmonary hypertension of the newborn. J Trop Pediatr 2004;50:219-223
62. American Gastroenterology Association medical position statement: Guidelines on constipation. Gastroenterology 2000;119:1761-1778
63. Folden SL, Backer JH, Maynard F, et al. Practice Guidelines for the Management of Constipation in Adults. Glenview, IL: Rehabilitation Nursing Foundation; 2002
64. Eisen GM, Baron TH, Dominitz JA, et al. Acut colonic pseudo-obstruction. Gastrointest Endosc 2002;56:789-792
65. Polson J, Lee WM. American Associaton for the Study of Liver Diseases (AASLD) position paper: The management of acut liver failure. Hepatology 2005; 41:1179-1197.